In re Par Pharmaceutical, Inc. Securities Litigation

133 F.R.D. 12, 1990 WL 177733
District Court, S.D. New York·Decided October 31, 1990·No. Master File No. 88 Civ. 8154 (RPP)·Published·Cited by 62 cases

Opinion

OPINION AND ORDER

ROBERT P. PATTERSON, Jr., District Judge.

The facts underlying this class action are fully set forth in this Court’s earlier opinion, In re Par Pharmaceutical Sec. Litig., 733 F.Supp. 668 (S.D.N.Y.1990). Defendants Ashok Patel, R.K. Patel and Dilip Shah now move for a limited stay of the proceedings and for an order staying discovery. The basis for defendants’ motions is that each is the target of an ongoing criminal investigation and, absent a stay, they will be forced to choose between waiving the Fifth Amendment privilege, risking self-incrimination, and invoking it, risking adverse inferences and inhibiting their ability to defend the instant action. For the reasons set forth below, defendants’ motions are denied.

Granting a stay of a civil proceeding when there exists a pending parallel criminal investigation is appropriate when justice so requires. United States v. Kordel, 397 U.S. 1, 12 n. 27, 90 S.Ct. 763, 770 n. 27, 25 L.Ed.2d 1 (1970). The civil action, if not stayed, might undermine the party’s Fifth Amendment privilege against self-incrimination, expand the rights of criminal discovery beyond the limits of Federal Rule of Criminal Procedure 16(b), expose the basis of the defense to the prosecution in advance of trial or otherwise prejudice the case. See S.E.C. v. Dresser Indus., Inc., 628 F.2d 1368, 1376 (D.C.Cir.), cert. denied, 449 U.S. 993, 101 S.Ct. 529, 66 L.Ed.2d 289 (1980).

A total stay of civil discovery pending the outcome of related criminal proceedings, however, is an extraordinary remedy. Weil v. Markowitz, 829 F.2d 166, 174 n. 17 (D.C.Cir.1987). The weight of authority in this Circuit indicates that courts will stay a civil proceeding when the criminal investigation has ripened into an indictment, see United States v. Certain Real Property, 751 F.Supp. 1060 (E.D.N.Y.1989) (LEXIS, Genfed library, Dist File) (granting stay where one of two moving defendants had been indicted)1; Clark v. United States, 481 F.Supp. 1086, 1097 n. 11 & 1099-1100 (S.D.N.Y.1979) (civil action stayed where at least one of three moving defendants had been indicted); Corbin v. Federal Deposit [14]*14Ins. Corp., 74 F.R.D. 147 (E.D.N.Y.1977); Dienstag v. Bronsen, 49 F.R.D. 327 (S.D.N.Y.1970); but will deny a stay of the civil proceeding where no indictment has issued, see S.E.C. v. First Jersey Sec. Inc., Fed. Sec.L.Rep. (CCH) ¶ 93,204, 1987 WL 8655 (S.D.N.Y. March 26, 1987).2

Ashok Patel, R.K. Patel and Dilip Shah are allegedly targets of continuing grand jury investigations conducted by the United States Attorney for the District of Maryland. Krulwich Aff. 113-4; Hardin Aff. II4; Salky Aff. 11 5. No indictments, however, have yet issued as a result of these investigations. The weight of authority thus counsels against granting a stay as to these defendants.

A few courts in this Circuit have stayed civil proceedings prior to the return of indictments in parallel criminal actions. See, e.g., Kashi v. Gratsos, 790 F.2d 1050 (2d Cir.1986).3 A pre-indictment stay is particularly appropriate where both the civil and criminal charges arise from the same remedial statute such that the criminal investigation is likely to vindicate the same public interest as would the civil suit. See Brock v. Tolkow, 109 F.R.D. 116 (E.D.N.Y.1985) (civil and criminal ERISA violations). In this case, however, the criminal investigations involve misconduct before the Food and Drug Administration while the civil action essentially involves the federal securities laws. Because it cannot be said that the two actions will vindicate the same or substantially the same public interest, a pre-indictment stay does not appear warranted in this action.

Accordingly, defendants’ motion for a limited stay of proceedings and for an order staying discovery are denied.

SO ORDERED.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Par Pharmaceutical, Inc. Securities Litigation, 133 F.R.D. 12, 1990 WL 177733 (S.D.N.Y. 1990).

133 F.R.D. 12 (In re Par Pharmaceutical, Inc. Securities Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related